Does Modality of Adjuvant Chemotherapy After Interval Surgical Debulking Matter in Epithelial Ovarian Cancer?
Authors:
- 1 March 2014
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 24 (3) , 461-467
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21 StudiesAnnals of Surgical Oncology, 2009
- Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009Gynecologic Oncology, 2009
- A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancerInternational Journal of Gynecological Cancer, 2007
- Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreductionGynecologic Oncology, 2007
- Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysisGynecologic Oncology, 2006
- Identification of Prognostic Factors in Advanced Epithelial Ovarian CarcinomaGynecologic Oncology, 2001
- Intraperitoneal cisplatin‐based chemotherapy vs. intravenous cisplatin‐based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancerInternational Journal of Gynecology & Obstetrics, 2001
- A Critique of Surgical Cytoreduction in Advanced Ovarian CancerGynecologic Oncology, 2000
- A Comparison of Intravenous versus Intraperitoneal Chemotherapy for the Initial Treatment of Ovarian CancerGynecologic Oncology, 1994